Core Insights - UNITY Biotechnology, Inc. has appointed Dr. Yehia Hashad to its board of directors and science committee, enhancing its leadership in ophthalmology as it prepares for the Phase 2b ASPIRE trial data readout for UBX1325 [1][2] Company Overview - UNITY is focused on developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging, particularly in ophthalmologic and neurologic fields [4] Leadership and Expertise - Dr. Hashad brings over 25 years of experience in clinical and commercial drug development, having previously held leadership roles at Bausch + Lomb and Allergan Aesthetics, overseeing numerous pharmaceutical programs [2][3] - His expertise in ophthalmology is expected to be crucial for advancing UBX1325, a treatment for diabetic macular edema [2][3] Strategic Goals - The company aims to leverage Dr. Hashad's insights to optimize its strategy for UBX1325 and to develop a robust pipeline of future products targeting retinal diseases [2][3]